Skip to main content
UniHealth

Doctor search

Mindie Nguyen, MD

Gastroenterology · Stanford

NPI 1164558326

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
5
2 carriers
Offices
6

Offices

6 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

5 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nguyen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

5 of 5 plans

Plans whose provider directory lists this clinician
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G79013 · Current

Licensed to practise in California · since 1994 · expires 2027-10-31 · University of California, San Diego School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$56,770

Medicare paid this office $56,770 for 221 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)167$35,242$103
Long return visit (40+ min)43$9,444$160
New patient visit (60+ min)20$3,375$169
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$2,448$106
New patient visit (45+ min)12$1,511$126
See all 7 services
Every Original Medicare service billed
Return visit (30+ min)167$35,242$103
Long return visit (40+ min)43$9,444$160
New patient visit (60+ min)20$3,375$169
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$2,448$106
New patient visit (45+ min)12$1,511$126
Short return visit (20+ min)13$818$55
Measurement of liver stiffness26$217$8

Who their Medicare patients are

221 Original Medicare patients in 2024. Average age 73 · Under 65 6% · 85 and older 8% · Women 55% · Also on Medicaid 37% · Health risk score 1.96. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.

Conditions among them: High blood pressure 73% · Diabetes 45% · Chronic kidney disease 32% · Coronary heart disease 22% · Heart failure 20% · Atrial fibrillation 20% · Depression 18% · COPD 16% · Cancer 14% · Dementia 9% · Stroke 5%.

The office billed $270,109, Medicare allowed $78,266 and paid $56,770; for 529 services of 13 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024221529731.96$270,109$56,770
2023182329722.01$165,742$30,451
2022216545712.48$282,031$48,743
2021190658712.26$321,819$61,241
2020188541692.41$215,048$36,808
2019170333702.41$100,112$25,020
2018147282692.94$71,332$18,532
2017204495693.17$105,743$32,291
2016198468682.64$111,791$33,064
2015220503672.61$125,350$37,193
2014215655682.68$193,124$58,414
2013227631672.45$196,713$58,638

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 7 services

Original Medicare services billed in 2023
Return visit (30+ min)106$14,582$97
Return visit (30+ min)26$4,792$84
Long return visit (40+ min)20$3,285$149
New patient visit (60+ min)14$2,215$158
New patient visit (45+ min)13$1,701$131
Short return visit (20+ min)17$987$55
Telehealth originating site facility fee16$428$20

2022: 10 services

Original Medicare services billed in 2022
Return visit (30+ min)136$25,021$101
Return visit (30+ min)31$5,920$81
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$3,658$85
Long return visit (40+ min)19$3,223$146
Long return visit (40+ min)13$2,454$129
New patient visit (60+ min)13$2,357$181
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,475$123
Telehealth originating site facility fee40$1,212$21
Short return visit (20+ min)13$826$59
Measurement of liver stiffness13$126$10

2021: 7 services

Original Medicare services billed in 2021
Return visit (30+ min)132$28,041$101
Long return visit (40+ min)37$9,451$166
Return visit (30+ min)32$8,803$91
Long return visit (40+ min)18$3,670$131
New patient visit (60+ min)13$2,342$180
Telehealth originating site facility fee51$1,980$21
Measurement of liver stiffness13$123$9

2020: 8 services

Original Medicare services billed in 2020
Return visit (30+ min)124$15,588$74
Return visit (30+ min)35$7,407$67
New patient visit (45+ min)16$1,894$118
Long return visit (40+ min)16$1,799$112
Telephone medical discussion with physician, 21-30 minutes14$1,710$95
Telehealth originating site facility fee52$1,601$22
Short return visit (20+ min)26$1,213$45
Telephone medical discussion with physician, 21-30 minutes11$1,052$75

2019: 4 services

Original Medicare services billed in 2019
Return visit (30+ min)99$12,939$81
Return visit (30+ min)39$6,370$68
Short return visit (20+ min)41$2,205$48
New patient visit (45+ min)16$1,850$116

2018: 4 services

Original Medicare services billed in 2018
Return visit (30+ min)59$6,481$64
Return visit (30+ min)45$5,445$84
Short return visit (20+ min)33$2,001$56
Short return visit (20+ min)44$1,643$36

2017: 5 services

Original Medicare services billed in 2017
Return visit (30+ min)103$15,126$65
Return visit (30+ min)35$4,985$84
Short return visit (20+ min)61$3,222$40
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$2,008$65
Short return visit (20+ min)25$1,751$56

2016: 5 services

Original Medicare services billed in 2016
Return visit (30+ min)96$13,089$63
Return visit (30+ min)53$9,518$89
Short return visit (20+ min)44$2,370$44
New patient visit (45+ min)13$1,655$127
Short return visit (20+ min)20$1,237$52

2015: 6 services

Original Medicare services billed in 2015
Return visit (30+ min)101$12,913$63
Return visit (30+ min)65$10,605$91
Short return visit (20+ min)44$2,138$43
Short return visit (20+ min)28$2,074$61
New patient visit (45+ min)17$1,618$95
Long return visit (40+ min)12$1,192$99

2014: 8 services

Original Medicare services billed in 2014
Return visit (30+ min)73$17,128$95
Return visit (30+ min)91$12,344$65
Long return visit (40+ min)52$9,721$93
Long return visit (40+ min)27$5,975$130
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$4,713$92
Initial hospital care with moderate level of medical decision making at least 75 minutes11$1,821$166
New patient visit (45+ min)14$1,482$106
Short return visit (20+ min)13$591$45

2013: 7 services

Original Medicare services billed in 2013
Long return visit (40+ min)73$12,134$89
Return visit (30+ min)53$10,487$92
Long return visit (40+ min)39$9,764$127
Return visit (30+ min)92$9,484$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes15$6,424$90
New patient visit (60+ min)31$4,226$136
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,642$176

Medicaid work

$5,728 in 2024

Medicaid paid $5,728 for 177 billed services this clinician did in 2024, up to 26 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)177$5,728
Medicaid work by year
2024177126$5,728
2023153129$3,044
2022237225$6,919
2021282228$7,433
2020247226$4,906
2019118127$1,952
2018102126$2,226
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)153$3,044

2022

Largest Medicaid services in 2022
Return visit (30+ min)224$6,713
Telehealth originating site facility fee13$206

2021

Largest Medicaid services in 2021
Return visit (30+ min)270$7,283
Telehealth originating site facility fee12$150

2020

Largest Medicaid services in 2020
Return visit (30+ min)222$4,184
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES25$722

2019

Largest Medicaid services in 2019
Return visit (30+ min)118$1,952

2018

Largest Medicaid services in 2018
Return visit (30+ min)102$2,226

Drugs they prescribed that Part D paid

$613,860

Pharmacies billed $613,860 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 888) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.

637 generic and fewer than 11 brand-name prescriptions · $613,860 in drug cost · 57 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Vemlidy174$257,710$1,481
Xifaxan48$160,049$3,334
Entecavir109$24,785$227
Tacrolimus88$13,614$155
Sirolimus26$9,478$365
See all 19 drugs
Every Part D drug this clinician prescribed
Vemlidy174$257,710$1,481
Xifaxan48$160,049$3,334
Entecavir109$24,785$227
Tacrolimus88$13,614$155
Sirolimus26$9,478$365
Mycophenolate Mofetil57$4,662$82
Ursodiol11$2,542$231
Cyclosporine Modified31$2,536$82
Tenofovir Disoproxil32$1,350$42
Azathioprine12$514$43
Pantoprazole51$484$9
Mycophenolic Acid13$349$27
Fludrocortisone Acetate18$249$14
Amlodipine Besylate44$201$5
Lactulose12$100$8
Spironolactone11$95$9
Tamsulosin16$64$4
Carvedilol13$44$3
Metoprolol11$31$3

Year by year

Part D prescribing by year
2024888910% (0)None$613,860
2023863810% (0)None$474,577
2022922970% (0)29%$493,437
20218521050% (0)32%$502,987
20208441000% (0)None$563,705
2019852890% (0)None$386,691
20181,14495None26%$1,024,823
20171,3451140% (0)34%$2,152,437
20161,480122None35%$2,923,722
20151,5591231% (22)None$2,662,273
20141,3911231% (15)45%$3,281,095
20139921081% (13)50%$667,176

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 17 drugs

Part D drugs prescribed in 2023
Vemlidy166$237,852$1,433
Xifaxan49$167,080$3,410
Entecavir86$23,027$268
Tacrolimus93$13,181$142
Sirolimus26$11,046$425
Mycophenolic Acid12$3,330$277
Ursodiol11$3,213$292
Cyclosporine Modified30$3,080$103
Mycophenolate Mofetil51$2,102$41
Lactulose18$1,289$72
Pantoprazole44$766$17
Amlodipine Besylate44$669$15
Tenofovir Disoproxil25$514$21
Azathioprine11$491$45
Fludrocortisone Acetate21$346$16
Metoprolol15$91$6
Furosemide12$81$7

2022: 20 drugs

Part D drugs prescribed in 2022
Xifaxan69$218,228$3,163
Vemlidy146$195,206$1,337
Entecavir105$27,134$258
Sirolimus48$12,762$266
Tacrolimus75$6,054$81
Mycophenolic Acid13$3,607$277
Ursodiol13$3,023$233
Cyclosporine Modified27$2,735$101
Mycophenolate Mofetil24$2,470$103
Tenofovir Disoproxil31$1,572$51
Lactulose23$1,333$58
Pantoprazole41$780$19
Fludrocortisone Acetate31$556$18
Azathioprine12$449$37
Gabapentin13$399$31
Potassium Chloride13$397$31
Amlodipine Besylate35$365$10
Glipizide18$275$15
Furosemide33$155$5
Ciprofloxacin16$117$7

2021: 21 drugs

Part D drugs prescribed in 2021
Vemlidy162$205,775$1,270
Xifaxan55$158,794$2,887
Entecavir73$21,369$293
Sirolimus45$16,238$361
Ursodiol28$5,073$181
Mycophenolic Acid12$3,779$315
Tacrolimus32$2,846$89
Cyclosporine Modified22$2,753$125
Mycophenolate Mofetil34$2,633$77
Tenofovir Disoproxil25$2,356$94
Generlac11$1,149$104
Azathioprine18$725$40
Gabapentin12$706$59
Pantoprazole36$678$19
Lactulose16$507$32
Amlodipine Besylate48$347$7
Spironolactone13$219$17
Omeprazole17$217$13
Furosemide30$175$6
Hydroxyzine11$89$8
Atorvastatin12$40$3

2020: 19 drugs

Part D drugs prescribed in 2020
Vemlidy162$206,338$1,274
Xifaxan51$144,517$2,834
Entecavir92$32,212$350
Baraclude14$19,791$1,414
Viread12$15,894$1,325
Sirolimus41$13,075$319
Ursodiol24$8,923$372
Tacrolimus39$6,252$160
Cyclosporine Modified36$5,401$150
Mycophenolate Mofetil52$3,681$71
Tenofovir Disoproxil26$3,673$141
Mycophenolic Acid12$3,057$255
Azathioprine12$403$34
Pantoprazole32$328$10
Spironolactone18$251$14
Omeprazole18$187$10
Potassium Chloride11$180$16
Furosemide32$169$5
Amlodipine Besylate31$104$3

2019: 21 drugs

Part D drugs prescribed in 2019
Xifaxan54$128,905$2,387
Vemlidy84$97,200$1,157
Entecavir104$19,440$187
Viread12$15,168$1,264
Ursodiol21$10,195$485
Sirolimus32$9,475$296
Tacrolimus55$6,885$125
Cyclosporine Modified27$4,159$154
Mycophenolate Mofetil59$4,011$68
Tenofovir Disoproxil19$3,370$177
Pantoprazole40$459$11
Spironolactone39$408$10
Fludrocortisone Acetate15$346$23
Quetiapine12$235$20
Amlodipine Besylate28$228$8
Atorvastatin11$156$14
Furosemide28$136$5
Glipizide16$117$7
Omeprazole16$103$6
Losartan24$80$3
Metoprolol13$44$3

2018: 32 drugs

Part D drugs prescribed in 2018
Nexavar14$134,015$9,572
Xifaxan41$89,323$2,179
Vemlidy70$89,206$1,274
Entecavir128$78,338$612
Baraclude29$39,983$1,379
Viread16$21,280$1,330
Ursodiol51$14,732$289
Sirolimus42$11,667$278
Mycophenolate Mofetil58$7,516$130
Tacrolimus54$4,564$85
Cyclosporine Modified25$3,849$154
Ultra-Fine Nano Pen Needle20$1,399$70
Generlac18$1,028$57
Lactulose30$900$30
Pantoprazole50$596$12
Spironolactone35$542$15
Potassium Chloride11$419$38
Glipizide Er11$271$25
Omeprazole50$240$5
Nifedipine Er11$213$19
Atorvastatin11$175$16
Furosemide32$136$4
Acyclovir13$124$10
Ciprofloxacin11$123$11
Quetiapine13$104$8
Polyethylene Glycol 335014$91$6
Amlodipine Besylate22$83$4
Famotidine12$79$7
Lisinopril12$79$7
Metoprolol25$64$3
Triamcinolone Acetonide11$55$5
Simvastatin20$49$2

2017: 37 drugs

Part D drugs prescribed in 2017
Epclusa31$783,903$25,287
Harvoni12$388,852$32,404
Nexavar28$275,169$9,827
Xifaxan65$132,673$2,041
Viread79$95,770$1,212
Entecavir111$80,926$729
Procrit16$57,828$3,614
Baraclude36$51,994$1,444
Vemlidy35$35,785$1,022
Ursodiol54$20,724$384
Sirolimus38$11,010$290
Mycophenolate Mofetil73$6,659$91
Tacrolimus61$6,380$105
Nexium22$5,636$256
Cyclosporine Modified24$3,507$146
Lactulose42$1,764$42
Ribasphere17$1,251$74
Pantoprazole55$819$15
Ultra-Fine Nano Pen Needle14$737$53
Zonisamide11$505$46
Spironolactone29$381$13
Azathioprine15$276$18
Omeprazole49$269$5
Nifedipine Er11$252$23
Furosemide41$251$6
Megestrol Acetate14$236$17
Metoprolol28$212$8
Amlodipine Besylate34$166$5
Hydralazine13$146$11
Clonidine18$127$7
Acyclovir12$121$10
Lisinopril17$121$7
Carvedilol17$120$7
Famotidine17$96$6
Quetiapine12$87$7
Ciprofloxacin11$67$6
Simvastatin20$44$2

2016: 32 drugs

Part D drugs prescribed in 2016
Harvoni29$924,127$31,866
Sovaldi16$436,372$27,273
Epclusa15$373,685$24,912
Nexavar28$281,969$10,070
Daklinza12$252,092$21,008
Entecavir165$151,999$921
Xifaxan77$143,765$1,867
Viread92$102,112$1,110
Baraclude34$43,638$1,283
Ursodiol71$24,284$342
Nexium66$22,496$341
Tacrolimus101$12,621$125
Sirolimus25$10,273$411
Ribavirin12$5,511$459
Mycophenolate Mofetil69$4,013$58
Cyclosporine Modified18$2,780$154
Lactulose46$2,059$45
Pantoprazole44$818$19
Bd Ultra-Fine Pen Needle11$537$49
Potassium Chloride19$493$26
Megestrol Acetate28$463$17
Omeprazole65$306$5
Amlodipine Besylate62$255$4
Metoprolol31$198$6
Furosemide49$179$4
Nifedipine Er15$172$11
Hydralazine13$151$12
Clonidine15$88$6
Lisinopril16$74$5
Ranitidine14$58$4
Simvastatin17$40$2
Atenolol13$17$1

2015: 33 drugs

Part D drugs prescribed in 2015
Harvoni38$1,204,127$31,688
Sovaldi20$563,282$28,164
Nexavar23$266,336$11,580
Baraclude105$139,481$1,328
Xifaxan76$138,251$1,819
Viread88$83,241$946
Entecavir81$78,149$965
Ursodiol73$29,048$398
Nexium62$23,243$375
Prograf28$17,442$623
Tacrolimus101$12,740$126
Sirolimus14$8,813$630
Epivir Hbv11$5,857$532
Mycophenolate Mofetil59$3,451$58
Ribasphere16$2,049$128
Lactulose66$1,840$28
Pantoprazole34$950$28
Spironolactone45$637$14
Fludrocortisone Acetate43$619$14
Omeprazole83$566$7
Megestrol Acetate25$506$20
Furosemide74$355$5
Generlac13$299$23
Metoprolol29$278$10
Amlodipine Besylate57$241$4
Oxycodone14$179$13
Nifedipine Er12$165$14
Losartan19$120$6
Prednisone12$94$8
Ranitidine12$71$6
Lisinopril16$49$3
Simvastatin12$26$2
Atenolol11$18$2

2014: 30 drugs

Part D drugs prescribed in 2014
Sovaldi56$1,781,860$31,819
Olysio22$536,860$24,403
Nexavar23$251,905$10,952
Baraclude117$151,881$1,298
Xifaxan65$97,289$1,497
Viread73$65,377$896
Tacrolimus76$21,459$282
Nexium65$21,413$329
Ribapak11$13,938$1,267
Ursodiol52$9,976$192
Prograf18$9,767$543
Rapamune12$8,625$719
Mycophenolate Mofetil76$5,375$71
Ribavirin12$2,815$235
Spironolactone57$1,592$28
Ribasphere11$1,175$107
Lactulose30$927$31
Megestrol Acetate35$724$21
Pantoprazole34$557$16
Omeprazole54$549$10
Furosemide85$376$4
Fludrocortisone Acetate18$347$19
Metoprolol17$307$18
Amlodipine Besylate66$301$5
Generlac12$300$25
Azathioprine12$295$25
Nifedipine Er11$155$14
Sulfamethoxazole-Trimethoprim21$109$5
Citalopram Hbr12$97$8
Ranitidine12$73$6

2013: 24 drugs

Part D drugs prescribed in 2013
Nexavar29$283,280$9,768
Baraclude123$136,418$1,109
Xifaxan63$78,657$1,249
Viread51$43,734$858
Pegasys11$31,725$2,884
Tacrolimus40$16,601$415
Nexium37$11,184$302
Mycophenolate Mofetil33$3,676$111
Ursodiol42$2,628$63
Lactulose37$1,828$49
Spironolactone37$1,048$28
Pantoprazole15$692$46
Megestrol Acetate24$563$23
Amlodipine Besylate75$464$6
Potassium Chloride15$422$28
Omeprazole40$379$9
Furosemide82$343$4
Metoprolol13$298$23
Citalopram Hbr16$178$11
Famotidine13$124$10
Clonidine12$99$8
Temazepam12$89$7
Zolpidem13$59$5
Prednisone11$33$3

Money from drug and device companies

$125 in 2025

Industry payments by year
202511None$125
2022216$30,650$31,910
202144$5,882$5,914
202034$9,606$9,626
201912$2,450$2,520

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
GlaxoSmithKlineNone$125
1 payment
  • Meals · 2025-11-06 · $125
See the published payment
Every published payment
GlaxoSmithKlineMeals · 2025-11-06None$125
See earlier years (2022, 2021, 2020, 2019)

2022: $31,910

Payments by company in 2022
GlaxoSmithKlineNone$28,150
4 payments
  • Consulting · 2022-08-18 · $2,800
  • Consulting · 2022-03-10 · $12,838
  • Consulting · 2022-02-09 · $9,425
  • Consulting · 2022-01-20 · $3,087
ExelixisCabometyx$3,760
12 payments
  • Paid to speak or teach for Cabometyx · 2022-11-23 · $2,500
  • Travel for Cabometyx · 2022-10-28 · $65
  • Travel for Cabometyx · 2022-10-28 · $409
  • Travel for Cabometyx · 2022-10-28 · $224
  • Travel for Cabometyx · 2022-10-28 · $239
  • Travel for Cabometyx · 2022-10-28 · $83
  • Travel for Cabometyx · 2022-10-28 · $24
  • Meals for Cabometyx · 2022-10-28 · $14
  • Travel for Cabometyx · 2022-10-28 · $30
  • Travel for Cabometyx · 2022-10-28 · $21
  • Meals for Cabometyx · 2022-10-28 · $51
  • Meals for Cabometyx · 2022-10-28 · $101

2021: $5,914

Payments by company in 2021
Gilead SciencesNone$2,710
1 payment
  • Consulting · 2021-08-24 · $2,710
Intercept PharmaceuticalsNone$2,538
1 payment
  • Consulting · 2021-02-02 · $2,538
Janssen Scientific AffairsNone$634
1 payment
  • Royalties · 2021-08-27 · $634
Novo NordiskNone$32
1 payment
  • Education · 2021-02-25 · $32

2020: $9,626

Payments by company in 2020
Intercept PharmaceuticalsNone$8,881
2 payments
  • Consulting · 2020-10-13 · $2,356
  • Consulting · 2020-08-13 · $6,525
Eli Lilly andNone$725
1 payment
  • Consulting · 2020-09-24 · $725
AmgenEvenity$19
1 payment
  • Meals for Evenity · 2020-06-24 · $19

2019: $2,520

Payments by company in 2019
Gilead SciencesNone$2,520
2 payments
  • Meals · 2019-03-12 · $70
  • Consulting · 2019-01-17 · $2,450

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2019Their institution$1,128,624
Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide · 2019Their institution$803,693
Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2020Their institution$486,887
Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide · 2020Their institution$219,876
Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide · 2022Their institution$203,000
Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients Switched To Taf From Entecavir (Etv) · 2020Their institution$182,000
GlaxoSmithKline, LLC. · Phase 3 Multicenter, Randomized, Double-Blind, Study To Assess the Eff · 2024Their institution$147,485
Gilead Sciences, Inc. · Real-World Analysis of Hbv Data · 2019Their institution$128,670
Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2022Their institution$120,664
Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients Switched To Taf From Entecavir (Etv) · 2019Their institution$96,978
PFIZER INC. · A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study To Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 · 2021Their institution$71,704
Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2021Their institution$70,000
Gilead Sciences, Inc. · Hepatitis C Research Consortium (Hcrc) · 2020Their institution$70,000
PFIZER INC. · A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study To Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 · 2022Their institution$68,903
AstraZeneca Pharmaceuticals LP · Cosmos - A Phase Iia Randomized Double-Blind Placebo-Controlled Study To Evaluate the Safety Tolerability and Pharmacodynamics of Azd4831 in Participants With Non-Cirrhotic Non-Alcoholic Steatohepatitis (Nash) With Fibrosis · 2023Their institution$50,269
Gilead Sciences, Inc. · Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide · 2023Their institution$50,000
Gilead Sciences, Inc. · Real World Analysis of Hbv Data · 2020Their institution$47,760
PFIZER INC. · A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study To Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 · 2024Their institution$31,876
GlaxoSmithKline, LLC. · Phase 3 Multicenter, Randomized, Double-Blind, Study To Assess the Eff · 2025Their institution$18,864
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Negative, Chronic Hepatitis B · 2019Their institution$14,449
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Negative, Chronic Hepatitis B · 2020Their institution$13,413
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Efficacy and Safety of Tenofovir Alafenamide (Taf) Versus Tenofovir Disoproxil Fumarate (Tdf) in Virologically Suppressed Subjects With Chronic Hbv · 2019Their institution$10,890
AstraZeneca Pharmaceuticals LP · Cosmos - A Phase Iia Randomized Double-Blind Placebo-Controlled Study To Evaluate the Safety Tolerability and Pharmacodynamics of Azd4831 in Participants With Non-Cirrhotic Non-Alcoholic Steatohepatitis (Nash) With Fibrosis · 2024Their institution$10,705
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Positive, Chronic Hepatitis B · 2019Their institution$8,807
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Negative, Chronic Hepatitis B · 2021Their institution$8,357
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Positive, Chronic Hepatitis B · 2020Their institution$6,902
Gilead Sciences, Inc. · Real-C: Real-World Evidence From the Asia Liver Consortium for Hcv · 2024Their institution$6,800
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Positive, Chronic Hepatitis B · 2021Their institution$6,615
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Negative, Chronic Hepatitis B · 2022Their institution$6,000
Gilead Sciences, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study To Evaluate the Safety and Efficacy of Gs-9620 in Combination With Tenofovir Disoproxil Fumarate (Tdf) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment · 2019Their institution$5,281
PFIZER INC. · A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study To Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 · 2023Their institution$4,974
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Study To Evaluate the Safety and Efficacy of Tenofovir Alafenamide (Taf) 25 Mg Qd Versus Tenofovir Disoproxil Fumarate (Tdf) 300 Mg Qd for the Treatment of Hbeag-Positive, Chronic Hepatitis B · 2022Their institution$4,292
PFIZER INC. · A Phase 2a Randomized Doubleblind Placebocontrolled Doseranging Parallel Group Study To Evaluate Safety Tolerability and Pharmacodynamics of Pf05221304 Administered Daily for 16weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease · 2019Their institution$2,193
Gilead Sciences, Inc. · A Phase 2, Open-Label Study To Evaluate the Safety and Efficacy of Switching To Tenofovir Alafenamide (Taf) From Tenofovir Disoproxil Fumarate (Tdf) and/Or Other Oral Antiviral Treatment (Oav) in Virologically Suppressed Chronic Hepatitis B Subjects With Renal and/Or Hepatic Impairment · 2019Their institution$1,000

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1164558326
Licence
CA G79013California G79013: Current · expires 2027-10-31
Trained
University of California, San Diego School of Medicine, 1992
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Medicaid ID
CA 00G790130
Taxonomy
Federal specialty code 207RT0003X (207RT0003X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RI0008X (207RI0008X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2007-02-24
NPI last updated
2025-02-26
NPI record certified
2025-02-26

This is when the NPI record was last certified, not a medical board exam.